(NasdaqGM:NPCE), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged […]

(NASDAQ:SDGR), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Schrodinger, Inc. (“Schrodinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Schrodinger and certain of its officers and/or directors have engaged

(NasdaqGM:TVTX), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Travere and certain of its officers and/or directors have

(NASDAQ:SMLR), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Semler and certain of its officers and/or directors have

(NASDAQ:META), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Meta Platforms, Inc. (“Meta” or the “Company”) (NASDAQ: META). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Meta and certain of its officers and/or directors have

(NASDAQ:SVRA), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Savara and certain of its officers and/or directors have engaged

(NASDAQ:HNRG), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Hallador Energy Company (“Hallador” or the “Company”) (NASDAQ: HNRG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Hallador and certain of its officers and/or directors have

(NYSE:CAL), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Caleres and certain of its officers and/or directors have engaged

(NASDAQ:SNY), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in

(NASDAQ:NEOG), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Neogen and certain of its officers and/or directors have engaged